NASDAQ:SBOT - Stellar Biotechnologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.76 -0.01 (-0.56 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$1.75
Today's Range$1.73 - $1.76
52-Week Range$1.65 - $10.85
Volume1,223 shs
Average Volume2.47 million shs
Market Capitalization$5.83 million
P/E Ratio-0.51
Dividend YieldN/A
Beta0.22
Stellar Biotechnologies logoStellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Receive SBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBOT
CUSIPN/A
Phone805-488-2800

Debt

Debt-to-Equity RatioN/A
Current Ratio7.36
Quick Ratio7.02

Price-To-Earnings

Trailing P/E Ratio-0.51
Forward P/E Ratio-0.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$230,000.00
Price / Sales25.18
Cash FlowN/A
Price / CashN/A
Book Value$4.92 per share
Price / Book0.36

Profitability

EPS (Most Recent Fiscal Year)($3.43)
Net Income$-5,030,000.00
Net Margins-4,766.06%
Return on Equity-77.77%
Return on Assets-72.53%

Miscellaneous

Employees28
Outstanding Shares3,290,000
Market Cap$5.83

The Truth About Cryptocurrencies

Stellar Biotechnologies (NASDAQ:SBOT) Frequently Asked Questions

What is Stellar Biotechnologies' stock symbol?

Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."

When did Stellar Biotechnologies' stock split? How did Stellar Biotechnologies' stock split work?

Stellar Biotechnologies's stock reverse split before market open on Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of Stellar Biotechnologies stock prior to the reverse split would have 14 shares after the split.

How were Stellar Biotechnologies' earnings last quarter?

Stellar Biotechnologies Inc (NASDAQ:SBOT) announced its earnings results on Tuesday, May, 9th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.05) by $0.28. The biotechnology company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.33 million. Stellar Biotechnologies had a negative return on equity of 77.77% and a negative net margin of 4,766.06%. View Stellar Biotechnologies' Earnings History.

What is the consensus analysts' recommendation for Stellar Biotechnologies?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stellar Biotechnologies in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Stellar Biotechnologies' key competitors?

Who are Stellar Biotechnologies' key executives?

Stellar Biotechnologies' management team includes the folowing people:
  • Mr. Frank R. Oakes, Pres, CEO & Chairman of Board (Age 68)
  • Ms. Kathi Niffenegger CPA, CFO, Corp. Sec. & Principal Accounting Officer (Age 61)
  • Dr. Gregory T. Baxter, Exec. VP of Corp. Devel. (Age 59)
  • Mr. Gary Koppenjan, Sr. Director of Investor Relations & Communications
  • Brando Lincicum, Exec. Director of Aquaculture and Facility Operations

Has Stellar Biotechnologies been receiving favorable news coverage?

News stories about SBOT stock have trended somewhat negative this week, Accern reports. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stellar Biotechnologies earned a news impact score of -0.01 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Stellar Biotechnologies?

Shares of SBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stellar Biotechnologies' stock price today?

One share of SBOT stock can currently be purchased for approximately $1.76.

How big of a company is Stellar Biotechnologies?

Stellar Biotechnologies has a market capitalization of $5.83 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($3.43) on an earnings per share basis. Stellar Biotechnologies employs 28 workers across the globe.

How can I contact Stellar Biotechnologies?

Stellar Biotechnologies' mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company can be reached via phone at 805-488-2800 or via email at [email protected]


MarketBeat Community Rating for Stellar Biotechnologies (NASDAQ SBOT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  169
MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe SBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.